Sanofi's CD38-targeting antibody isatuximab could be the company's next new cancer drug as it looks to rebuild in oncology. The pharma said Feb. 4 that it will file isatuximab with regulatory authorities in the US and Europe in the first half of 2019 based on the positive results from a Phase III trial in relapsed/refractory multiple myeloma (r/rMM).
But isatuximab, if approved, will be in a come-from-behind position following Johnson & Johnson/Genmab AS's Darzalex (daratumumab), which was approved in June 2016 as the first human anti-CD38 monoclonal antibody to treat r/rMM
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?